韦氏活血通络方对气虚血瘀型前部缺血性视神经病变患者视野的影响

夏燕婷; 郝美玲; 张陶陶; 廖良

韦氏活血通络方对气虚血瘀型前部缺血性视神经病变患者视野的影响

1.
北京中医药大学东方医院，北京 100078
2.
北京中医药大学第二临床医学院，北京 100078

计量
- 文章访问数: 421
- HTML全文浏览量: 4
- PDF下载量: 382
- 被引次数: 0
出版历程
- 刊出日期: 2020-03-10

Effect of Wei's Huoxue Tongluo Formula on Anterior Ischemic Optic Neuropathy Patients with Qi Deficiency and Blood Stasis

1.
Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, 100078, China
2.
The Second Clinical Medical College, Beijing University of Chinese Medicine, Beijing, 100078, China

摘要

摘要: 目的评价韦氏活血通络方对气虚血瘀型前部缺血性视神经病变（AION）视野的影响。方法采用前瞻性随机对照试验的研究方法，观察2014年1月至2018年12月在北京中医药大学东方医院眼科门诊就诊的AION患者，纳入患者需同时符合AION和中医证型气虚血瘀型的诊断标准，共纳入患者63例99眼，随机分为试验组32例51眼，对照组31例48眼。试验组给予韦氏活血通络方中药配方颗粒剂冲服，对照组给予复方血栓通胶囊及甲钴胺片口服。治疗4周后，检测患者的视野平均缺损(MD)、丢失方差(LV)、平均敏感度(MS)、最佳矫正视力(BCVA)、化验指标等，进行疗效和安全性评价。结果患者视野缺损的形态主要包括以水平线为界的上方或下方近半盲(42.4%）、神经束样（含扇形、象限性）缺损(27.3%)、中心/类中心暗点(13.1%)等。治疗后，试验组和对照组采用G2程序检测的患者平均缺损（MD）值中位数分别为7.1 dB及10.8 dB，2组有显著性差异（P＜0.05），但丢失方差（LV）值无明显差异。治疗前后试验组MD改善幅度明显高于对照组（P＜0.01），治疗前后试验组最佳矫正视力的改善幅度明显高于对照组（P＜0.05）。采用LVC程序检测的患者治疗前后及组间平均敏感度（MS）值无统计学差异（P>0.05）。试验组头或眼刺痛、气短、倦怠懒言、舌淡或瘀斑、脉细涩等症状出现频次均明显低于对照组（P＜0.05）。全部患者治疗期间未发生明显不良事件。结论 AION的典型视野损害特征为水平半盲、神经束样缺损及中心/类中心暗点，韦氏活血通络方治疗可改善部分气虚血瘀型AION患者中医证候，提高患者视力、视野。
- 活血通络方 /
- 气虚血瘀 /
- 前部缺血性视神经病变 /
- 视野
Abstract: OBJECTIVE To evaluate the effect of Wei's Huoxue Tongluo formula on anterior ischemic optic neuropathy (AION) patients with qi deficiency and blood stasis. METHODS A prospective randomized controlled trial was conducted to observe the AION outpatients admitted in the Ophthalmology Department， Dongfang Hospital， Beijing University of Chinese Medicine from January 2014 to December 2018. The patients enrolled in the study were required to meet the diagnostic criteria of AION and TCM syndrome of qi deficiency and blood stasis. 63 patients (99 eyes) were included in the study. They were randomly divided into 32 cases (51 eyes) in the trial group and 31 cases (48 eyes) in the control group. The trial group was given Wei's Huoxue Tongluo formula granule， while the control group was given Complex Thrombolysis capsule and Mecobalamin tablets. After 4 weeks' treatment， the mean defect (MD)， loss variance (LV)， mean sensitivity (MS) of visual field， and， best corrected visual acuity (BCVA) and whole blood count， serum transaminase and creatinine were measured to evaluate the efficacy and safety. RESULTS The visual field defects of the patients mainly included nearly half-blind (42.4%) in upper or lower field of the horizontal line， fascicular (including fan-shaped and quadrantal) defects (27.3%)， and central or quasi central scotoma(13.1%). After treatment， the median values of MD in the trial group and the control group were 7.1 db and 10.8 db， respectively. There was a significant difference between the two groups (P<0.05)， but no significant difference in LV. After treatment， the improvement of MD in the trial group was significantly higher than that in the control group (P<0.01)， and the improvement of BCVA in the trial group was significantly higher than that in the control group (P<0.05). There was no significant difference in MS before and after treatment and between groups (P>0.05). The frequency of symptoms such as head or eye tingling， shortness of breath， languor and laziness， light tongue or ecchymosis， thin and rough pulse in the trial group was significantly lower than that in the control group (P<0.05). No side effects occurred in patients during the treatment. CONCLUSION The typical visual field defect of AION are horizontal hemiblindness， fascicular defect and center or quasi center scotoma. The treatment of Wei's Huoxue Tongluo formula can improve some TCM symptoms for AION patients with qi deficiency and blood stasis， and improve their vision acuity and visual field.
- Huoxue Tongluo formula /
- qi deficiency and blood stasis /
- anterior ischemic optic neuropathy /
- visual field

HTML全文

参考文献(19)

[1]	HAYREH SS. Is chemic optic neuropathies? Where are we now?[J]. Graefes Arch Clin Exp Opthalmol， 2013，251(8): 1873-1874.
[2]	朱成义，伊琼，马金力，等.活血通络颗粒对缺血性视神经病变的临床研究[J].国际眼科杂志，2015，15（11）：1945-1948.
[3]	HAYREH SS. Ischemic optic neuropathy[J]. Prog Retin Eye Res， 2009，28(1):34-62.
[4]	国家中医药管理局医政司.24个专业105个病种中医临床路径·目系暴盲[Z].2012:292-297.
[5]	HAYREH SS， ZIMMERMAN MB. Nonarteritic anterior ischemic optic neuropathy: Clinical characteristics in diabetic patients versus nondiabetic patients[J]. Ophthalmology，2008，115: 1818-1825.
[6]	中华医学会眼科分会神经眼科学组.我国非动脉炎性前部缺血性视神经病变诊断和治疗专家共识（2015）[J].中华眼科杂志，2015，51（5）：323-326.
[7]	〖JP2〗HAYREH SS， ZIMMERMAN MB. Non-arteritic anterior is chemic optic neuropathy: Role of systemic corticosteroid therapy[J]. Graefes Arch Clin Exp Ophthalmol， 2008，246: 1029-1046.〖JP〗
[8]	〖JP2〗张晓，李旭，翟瑜如，等.全身应用皮质类固醇类药物对缺血性视神经病变影响的Meta分析[J].中国老年学杂志，2012，32：4170-4171.〖JP〗
[9]	〖JP2〗PARISI V， BARBANO L， DI RENZO A， et al.Neuroenhancement and neuroprotection by oral solution citicoline in non-arteritic ischemic optic neuropathy as a model of neurodegeneration: A randomized pilot study[J]. PLoS ONE， 2019， 14(7):e0220435.〖JP〗
[10]	RATH E， HAZAN Z， ADAMSKY K， et al. Randomized controlled phase 2a study of RPh201 in previous nonarteritic anterior is chemic optic neuropathy[J]. J Neuro ophthalmol， 2019， 39(3):291-298.
[11]	SOLANO EC， KORNBRUST DJ， BEAUDRY A， et al. Toxicological and pharmacokinetic properties of QPI-1007， a chemically modified synthetic siRNA targeting caspase 2 mRNA， following intravitreal injection[J]. Nucleic Acid Ther， 2014， 24(4):258-66.
[12]	HAYREH SS. Controversies on neuroprotection therapy in non-arteritic anterior ischaemic optic neuropathy[J]. Br J Ophthalmol， 2020，104:153-156.
[13]	廖良，韦企平.韦企平治疗非动脉炎性前部缺血性视神经病变临证经验[J].中国中医眼科杂志，2014，24（5）：360-362.
[14]	廖良，孔莹莹，韦企平，等.黄芪注射液对体外培养视网膜神经节细胞的保护作用[J].眼科新进展，2010，30（12）：1101-1104.
[15]	廖良，韦企平，周剑，等. 双眼非动脉炎性前部缺血性视神经病变患者的临床特点和预后分析[J].国际眼科杂志，2015，15（9）：1500-1506.
[16]	廖良，宫晓红，韦企平，等.银杏叶提取物和灯盏花素治疗非动脉炎性前部缺血性视神经病变的对比研究[J].眼科新进展，2015，35（3）：240-242.
[17]	OLVER JM， SPALTON DJ， MCCARTNEY AC. Microvascular study of the retrolaminar optic nerve in man: The possible significance in anterior ischaemic optic neuropathy[J]. Eye (Lond)， 1990，4(1):7-24.
[18]	宋宏鲁.非动脉炎性前部缺血性视神经病变的临床分析[D].西安:第四军医大学，2010.
[19]	张靖.前部缺血性视神经病变临床检查及危险因素研究[D].重庆:重庆医科大学，2011.